Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02483182
Other study ID # ZEP - 002 - IL
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 2015
Est. completion date June 24, 2018

Study information

Verified date April 2018
Source Shulov Innovate for Science Ltd. 2012
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase II, prospective, randomized, double-blind, parallel group, acyclovir-controlled clinical study to evaluate the safety, tolerability and preliminary therapeutic efficacy of ZEP-3 ointment 1.0% for the treatment of cold sores (Herpes labialis), following five consecutive treatment days with five times daily topical administration.


Description:

The primary endpoint of this study are:

- "Time to healing" - Clinician-assessed duration in days of herpes labialis episode.

- Patient-assessed duration and intensity of pain by Visual Analog Scale (VAS).

- Safety and tolerability following five consecutive treatment days with five times daily topical administration.

The secondary endpoints of this study are:

- Proportion of subjects with non - ulcerative herpes lesion.

- Time for herpes labialis recurrences

Subject safety will be assessed following treatment by ZEP-3 ointment 1.0% or acyclovir cream 5% treatment, using measurements of the following variables:

- Physical examination,

- Vital Signs (HR, BP, Body temperature),

- Adverse events recording and

- Concomitant medications


Recruitment information / eligibility

Status Completed
Enrollment 210
Est. completion date June 24, 2018
Est. primary completion date June 24, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

Prior to enrollment in this study, candidates must meet ALL of the following inclusion criteria:

1. Patients suffering from recurrent Herpes labialis with history of at least 3 cold sores recurrences during the previous 12 months.

2. Participants, either male or female are between 18 and 75 years of age.

3. Patients arrive at the clinic with any symptom of an acute Herpes labialis episode.

Or, patients arrive at the clinic within 48 hours of treatment initiation for a recurrent Herpes labialis episode.

4. Patients with previous Herpes labialis episode must be healed for at least 14 days before baseline visit

5. Patients with no history of reaction to topical products.

6. Female subjects of childbearing potential must have a negative pregnancy test at screening and agree to use a proper contraceptive method during the study.

7. Participant understands the nature of the procedure and is willing and able to comply with all requirement of the protocol.

8. Patient is willing and able to provide written informed consent prior to any study procedure.

Exclusion Criteria:

1. Subject has abnormal skin conditions or significant facial hair at or near the investigational area

2. Subject has any body piercing in or around the area ordinarily affected by cold sores.

3. Subjects with a history of cardiac abnormalities.

4. Subject has a recent history of renal dysfunction or serious hepatic disease

5. Subject has an active malignancy or immunodeficient disease

6. Subject who is unwilling to stop using topical medical, OTC, cosmetics or facial skin care products in or around the oral area during the study period.

7. Subject requires chronic use of immunomodifying drugs or topical steroids on or near the face.

8. Subject requires chronic use of anti-viral medication.

9. Subject requires chronic use of analgesics, pain medication or non-steroidal anti inflammatory agents (NSAIDs).

10. History of allergic or adverse response to acyclovir, or any related anti-viral drug.

11. Subject has had an infection with HSV-1 isolates know to be resistant to acyclovir, valacyclovir, famciclovir, or ganciclovir.

12. Subject has had a herpes vaccine.

13. Females during pregnancy, lactation or breastfeeding.

14. Subject has a history of alcoholism or drug abuse within the preceding 12 months.

15. Subject is currently enrolled in another clinical trial involving the use of a drug and/or a device.

16. Any history which, in the Investigator's judgment, makes the subject ineligible or places the subject at undue risk.

17. Subjects with immune deficiency conditions including acquired immune deficiency.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ZEP-3 ointment 1.0%

Acyclovir cream 5%


Locations

Country Name City State
Israel Dermatology out-patients clinic, Lev Hayasmin MC Netanya

Sponsors (1)

Lead Sponsor Collaborator
Shulov Innovate for Science Ltd. 2012

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinician-assessed "Time to healing" Up to 14 days
Secondary Time for Herpes labialis recurrences 12 months
See also
  Status Clinical Trial Phase
Completed NCT00297011 - Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis Phase 2
Completed NCT03310294 - Immune Evidence to the Consumption of Lactobacillus GG and FOS Consumption in Patients With Herpes Labialis N/A
Terminated NCT04539483 - Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection Phase 2
Completed NCT02265913 - Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis Phase 3
Completed NCT01971385 - Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis Phase 1
Active, not recruiting NCT01695187 - NB-001 Treatment of Recurrent Herpes Labialis Phase 3
Completed NCT00375570 - Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in Adolescents Phase 3
Completed NCT02871492 - Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes Phase 2
Completed NCT01484067 - Study of a Cold Sore Patch for the Treatment of Herpes Labialis N/A
Completed NCT00769314 - Phase 3 Clinical Study for the Treatment of Cold Sore Phase 3
Completed NCT00878072 - Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis Phase 2/Phase 3
Completed NCT01574612 - Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old Phase 3
Completed NCT03661541 - Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1) Phase 1
Recruiting NCT01306084 - Viral Infections in Healthy and Immunocompromised Hosts
Terminated NCT03521479 - A Phase 2, Muti-Center Study of Repeat Dosing of Squaric Acid Dibutyl Ester in Subjects With Herpes Labialis Phase 2
Terminated NCT00913692 - A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis Phase 2
Completed NCT02207881 - A Double-Blind, Randomized, Placebo-Controlled Study of Topical VDO for the Treatment of Herpes Simplex Labialis Phase 2
Completed NCT01653509 - An Exploratory Study to Investigate the Inflammatory Response During a Cold Sore Episode Phase 1
Completed NCT00361881 - Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis Phase 3
Recruiting NCT02582086 - Study of a New Topical Natural Health Product for the Treatment of Herpes Labialis N/A